KBC Group NV Purchases 126,230 Shares of Xenon Pharmaceuticals Inc. $XENE

Posted by Brian Himes on Jul 23rd, 2026

KBC Group NV grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 4,540.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 129,010 shares of the biopharmaceutical company’s stock after purchasing an additional 126,230 shares during the quarter. KBC Group NV’s holdings in Xenon Pharmaceuticals were worth $7,502,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Cinctive Capital Management LP boosted its holdings in shares of Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after buying an additional 263 shares during the last quarter. State of Wyoming increased its holdings in Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the last quarter. Quarry LP raised its position in Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares during the period. Altfest L J & Co. Inc. raised its position in Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 501 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Xenon Pharmaceuticals by 11.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 675 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on XENE. Wells Fargo & Company reissued an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. JPMorgan Chase & Co. lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Royal Bank Of Canada upped their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $77.20.

Get Our Latest Analysis on Xenon Pharmaceuticals

Xenon Pharmaceuticals Trading Down 0.8%

NASDAQ XENE opened at $66.18 on Thursday. The stock’s 50 day moving average is $57.89 and its 200 day moving average is $52.38. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $72.66. The stock has a market cap of $6.40 billion, a PE ratio of -14.08 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the business earned ($0.83) EPS. On average, analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is currently owned by corporate insiders.

Xenon Pharmaceuticals Profile

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.